litlas
ログインアカウント作成

Maurie Markman

1984–2019 年に発表

93
論文数
22,787
被引用数
83
h 指数
93
i10 指数

被引用数

Maurie Markman の年別被引用数1985 年: 被引用 5 件1986 年: 被引用 11 件1987 年: 被引用 6 件1988 年: 被引用 8 件1989 年: 被引用 11 件1990 年: 被引用 4 件1991 年: 被引用 9 件1992 年: 被引用 15 件1993 年: 被引用 26 件1994 年: 被引用 16 件1995 年: 被引用 16 件1996 年: 被引用 24 件1997 年: 被引用 21 件1998 年: 被引用 40 件1999 年: 被引用 37 件2000 年: 被引用 41 件2001 年: 被引用 61 件2002 年: 被引用 70 件2003 年: 被引用 102 件2004 年: 被引用 97 件2005 年: 被引用 118 件2006 年: 被引用 135 件2007 年: 被引用 149 件2008 年: 被引用 136 件2009 年: 被引用 167 件2010 年: 被引用 145 件2011 年: 被引用 152 件2012 年: 被引用 161 件2013 年: 被引用 110 件2014 年: 被引用 204 件2015 年: 被引用 472 件2016 年: 被引用 320 件2017 年: 被引用 187 件2018 年: 被引用 131 件2019 年: 被引用 570 件2020 年: 被引用 425 件2021 年: 被引用 322 件2022 年: 被引用 259 件2023 年: 被引用 134 件2024 年: 被引用 196 件2025 年: 被引用 73 件2026 年: 被引用 2 件

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 1,986 件、この内訳の 30%中国: 引用元論文 808 件、この内訳の 12.2%イギリス: 引用元論文 346 件、この内訳の 5.2%イタリア: 引用元論文 343 件、この内訳の 5.2%カナダ: 引用元論文 249 件、この内訳の 3.8%ドイツ: 引用元論文 230 件、この内訳の 3.5%日本: 引用元論文 210 件、この内訳の 3.2%フランス: 引用元論文 209 件、この内訳の 3.2%オーストラリア: 引用元論文 177 件、この内訳の 2.7%オランダ: 引用元論文 176 件、この内訳の 2.7%スペイン: 引用元論文 152 件、この内訳の 2.3%韓国: 引用元論文 135 件、この内訳の 2%
0%30%その他 24%

機関

分野

  • Medicine62.9%
  • Biochemistry, Genetics and Molecular Biology25.8%
  • Materials Science2.6%
  • Immunology and Microbiology2.5%
  • Computer Science0.8%
  • Economics, Econometrics and Finance0.8%
  • その他4.6%

トピック

  • Ovarian cancer diagnosis and treatment8.8%
  • Intraperitoneal and Appendiceal Malignancies4.4%
  • PARP inhibition in cancer therapy3.3%
  • Endometrial and Cervical Cancer Treatments2.4%
  • Cancer-related molecular mechanisms research1.8%
  • MicroRNA in disease regulation1.6%
  • その他77.7%

共著者

全論文

検索で開く
  1. Signet-Ring Cell Carcinoma of the Colon: A Case Report and Review of the Literature

    著者: Peter Y. Park, Teresa A. Goldin, John C. S. Chang, Maurie Markman, Madappa N. Kundranda - Case Reports in Oncology 2015 被引用: 5,277

  2. Ovarian cancer

    著者: Bryan T. Hennessy, Robert L. Coleman, Maurie Markman - The Lancet 2009 被引用: 652

  3. Role of nutritional status in predicting quality of life outcomes in cancer – a systematic review of the epidemiological literature

    著者: C. G. Lis, Digant Gupta, C. A. Lammersfeld, Maurie Markman, Pankaj G. Vashi - Nutrition Journal 2012 被引用: 312

  4. Paclitaxel in cancer therapy

    著者: Maurie Markman, Tarek Mekhail - Expert Opinion on Pharmacotherapy 2002 被引用: 379

  5. Phase III Trial of Standard-Dose Intravenous Cisplatin Plus Paclitaxel Versus Moderately High-Dose Carboplatin Followed by Intravenous Paclitaxel and Intraperitoneal Cisplatin in Small-Volume Stage III Ovarian Carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group

    著者: Maurie Markman, Brian N. Bundy, David S. Alberts, Jeffrey M. Fowler, D L Clark-Pearson, Linda F. Carson, Scott Wadler, Joshua Z. Sickel - Journal of Clinical Oncology 2001 被引用: 1,088

  6. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.

    著者: Maurie Markman, Robert Rothman, Thomas B. Hakes, Bonnie Reichman, William J. Hoskins, Stephen C. Rubin, Wanda K. Jones, Lois Almadrones, John L. Lewis - Journal of Clinical Oncology 1991 被引用: 854

  7. Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study

    著者: William E. Winter, G. Larry Maxwell, Chunqiao Tian, Jay W. Carlson, Robert F. Ozols, Peter G. Rose, Maurie Markman, Deborah K. Armstrong, Franco M. Muggia, William P. McGuire - Journal of Clinical Oncology 2007 被引用: 846

  8. Clinical Features of Hypersensitivity Reactions to Carboplatin

    著者: Maurie Markman, Alexander Kennedy, Kenneth Webster, Paul Elson, Gertrude Peterson, Barbara Kulp, Jerome L. Belinson - Journal of Clinical Oncology 1999 被引用: 374

  9. Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer

    著者: Bryan T. Hennessy, Kirsten M. Timms, Mark Carey, Alexander Gutin, Larissa A. Meyer, Darl D. Flake, Victor Abkevich, Jennifer Potter, Dmitry Pruss, Pat Glenn, Yang Li, Jie Li, Ana M. González-Angulo, Karen McCune, Maurie Markman, Russell R. Broaddus, Jerry S. Lanchbury, Karen H. Lu, Gordon B. Mills - Journal of Clinical Oncology 2010 被引用: 373

  10. Long-Term Survival Advantage and Prognostic Factors Associated With Intraperitoneal Chemotherapy Treatment in Advanced Ovarian Cancer: A Gynecologic Oncology Group Study

    著者: Devansu Tewari, James Java, Ritu Salani, Deborah K. Armstrong, Maurie Markman, Thomas J. Herzog, Bradley J. Monk, John K. Chan - Journal of Clinical Oncology 2015 被引用: 286

  11. Intraperitoneal antineoplastic drug delivery: rationale and results

    著者: Maurie Markman - The Lancet Oncology 2003 被引用: 236

  12. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery

    著者: Arancha Prada-Villaverde, Jesús Esquivel, Andrew M. Lowy, Maurie Markman, Terence C. Chua, Joerg Pelz, Dario Baratti, Joel Baumgartner, Richard Berri, Pedro Bretcha-Boix, Marcello Deraco, Guillermo Flores-Ayala, Olivier Gléhen, Alberto Gómez-Portilla, Santiago González‐Moreno, Martin Goodman, Evgenia Halkia, Shigeki Kusamura, Mecker G. Möller, Guillaume Passot, Marc Pocard, George I. Salti, Armando Sardi, Maheswari Senthil, John Spiliotis, Juan Torres-Melero, Kiran K. Turaga, Richard Trout - Journal of Surgical Oncology 2014 被引用: 161

  13. Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: Results from a prospectively designed analysis of progression-free survival

    著者: David S. Alberts, Christian Marth, Ronald D. Alvarez, Gary A. Johnson, Mariusz Bidziński, David Kardatzke, Williamson Z. Bradford, Jeff Loutit, David H. Kirn, Mary C. Clouser, Maurie Markman - Gynecologic Oncology 2008 被引用: 129

  14. National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000

    著者: Patricia J. Eifel, Jan Axelson, Janitha Costa, John Crowley, W.J. Curran, Amy M.B. Deshler, Sarah Fulton, Carolyn B. Hendricks, Margaret Kemeny, Alice B. Kornblith, Thomas A. Louis, Maurie Markman, Robert J. Mayer, Debra Roter - JNCI Journal of the National Cancer Institute 2001 被引用: 897

  15. Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study.

    著者: Maurie Markman, Eric K. Rowinsky, Thomas B. Hakes, Bonnie Reichman, Wanda K. Jones, Joanne Lewis, Stephen C. Rubin, John P. Curtin, R. Barakat, M. Phillips - Journal of Clinical Oncology 1992 被引用: 314

  16. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study.

    著者: Prudence A. Francis, Eric K. Rowinsky, Juliane Schneider, T. Hakes, William J. Hoskins, Maurie Markman - Journal of Clinical Oncology 1995 被引用: 196

  17. Primary ovarian cancer chemotherapy: current standards of care

    著者: William P. McGuire, Maurie Markman - British Journal of Cancer 2003 被引用: 168

  18. High-dose cisplatin with sodium thiosulfate protection.

    著者: C E Pfeifle, Stephen B. Howell, R D Felthouse, T B Woliver, Paul A. Andrews, Maurie Markman, Michael P. Murphy - Journal of Clinical Oncology 1985 被引用: 152

  19. Intravenous Vitamin C in the Supportive Care of Cancer Patients: A Review and Rational Approach

    著者: Eiko Klimant, Hugh Wright, Deborah C. Rubin, Dugald Seely, Maurie Markman - Current Oncology 2018 被引用: 103

  20. Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients

    著者: Marisa A. Navo, Anuradha Kunthur, Martina L. Badell, Larry Coffer, Maurie Markman, Jubilee Brown, Judith A. Smith - Gynecologic Oncology 2006 被引用: 96

  21. Phase III Randomized Trial of 12 Versus 3 Months of Maintenance Paclitaxel in Patients With Advanced Ovarian Cancer After Complete Response to Platinum and Paclitaxel-Based Chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group Trial

    著者: Maurie Markman, Pan Liu, Sharon P. Wilczynski, Bradley J. Monk, Larry J. Copeland, Ronald D. Alvarez, Caroline S. Jiang, David S. Alberts - Journal of Clinical Oncology 2003 被引用: 458

  22. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study

    著者: Maurie Markman, John A. Blessing, Stephen C. Rubin, Joseph P. Connor, Parviz Hanjani, Steven Waggoner - Gynecologic Oncology 2005 被引用: 244

  23. Paclitaxel-Associated Hypersensitivity Reactions: Experience of the Gynecologic Oncology Program of the Cleveland Clinic Cancer Center

    著者: Maurie Markman, Alexander Kennedy, Kenneth Webster, Barbara Kulp, Gertrude Peterson, Jerome L. Belinson - Journal of Clinical Oncology 2000 被引用: 193

  24. Phase 1b‐2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum‐resistant or platinum‐refractory epithelial ovarian cancer

    著者: Siqing Fu, Wei Hu, Revathy B. Iyer, John J. Kavanagh, Robert L. Coleman, Charles F. Levenback, Anil K. Sood, Judith K. Wolf, David M. Gershenson, Maurie Markman, Bryan T. Hennessy, Razelle Kurzrock, Robert C. Bast - Cancer 2010 被引用: 184